Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12407205 | 0.93 | CFTR (0.76) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12481851 | 0.92 | CFTR (0.58) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL15257480 | 0.90 | CFTR (0.58) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL24624753 | 0.90 | CFTR (0.62) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189027 | 0.89 | CFTR (0.67) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL18768743 | 0.89 | CFTR (0.58) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL15259099 | 0.89 | CFTR (0.58) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL13298585 | 0.88 | CFTR (0.57) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189346 | 0.87 | CFTR (0.60) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12407220 | 0.87 | CFTR (0.60) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | US | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-01-28 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
| US-7741321-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | CFTR 1/4885NR1I2 3051/4885ADORA3 705/4885 |
| US-10980746-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | CFTR 1/4885NR1I2 3051/4885ADORA3 705/4885 |
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | CFTR 1/4885NR1I2 595/4885ADORA3 592/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | CFTR 1/4885NR1I2 1234/4885ADORA3 654/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CFTR 1/4885NR1I2 767/4885ADORA3 514/4885 |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CFTR 1/4885NR1I2 767/4885ADORA3 514/4885 |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 435/4885ADORA3 187/4885 |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 391/4885ADORA3 216/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CFTR 1/4885NR1I2 767/4885ADORA3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.